BACKGROUND: We have previously demonstrated that heparin-binding EGF-like growth factor (HB-EGF) administration protects the intestines from ischemia/reperfusion (I/R) injury in vivo. We have also shown that HB-EGF promotes mesenchymal stem cell (MSC) proliferation and migration in vitro. The goals of the current study were to examine the effects of HB-EGF and both bone marrow (BM)- and amniotic fluid (AF)-derived MSC on intestinal I/R injury in vivo. MATERIALS AND METHODS: MSC were isolated from pan-EGFP mice, expanded, and purified. Pluripotency was confirmed by induced differentiation. Mice were subjected to terminal ileum I/R and received either: (1) no therapy; (2) HB-EGF; (3) BM-MSC; (4) HB-EGF+BM-MSC; (5) AF-MSC; or (6) HB-EGF+AF-MSC. MSC engraftment, histologic injury, and intestinal permeability were quantified. RESULTS: There was increased MSC engraftment into injured compared to uninjured intestine for all experimental groups, with significantly increased engraftment for AF-MSC+HB-EGF compared to AF-MSC alone. Administration of HB-EGF and MSC improved intestinal histology and intestinal permeability after I/R injury. The greatest improvement was with combined administration of HB-EGF+AF-MSC. CONCLUSIONS: Both HB-EGF alone and MSC alone can protect the intestines from I/R injury, with synergistic efficacy occurring when HB-EGF and AF-MSC are administered together.
BACKGROUND: We have previously demonstrated that heparin-binding EGF-like growth factor (HB-EGF) administration protects the intestines from ischemia/reperfusion (I/R) injury in vivo. We have also shown that HB-EGF promotes mesenchymal stem cell (MSC) proliferation and migration in vitro. The goals of the current study were to examine the effects of HB-EGF and both bone marrow (BM)- and amniotic fluid (AF)-derived MSC on intestinal I/R injury in vivo. MATERIALS AND METHODS:MSC were isolated from pan-EGFP mice, expanded, and purified. Pluripotency was confirmed by induced differentiation. Mice were subjected to terminal ileum I/R and received either: (1) no therapy; (2) HB-EGF; (3) BM-MSC; (4) HB-EGF+BM-MSC; (5) AF-MSC; or (6) HB-EGF+AF-MSC. MSC engraftment, histologic injury, and intestinal permeability were quantified. RESULTS: There was increased MSC engraftment into injured compared to uninjured intestine for all experimental groups, with significantly increased engraftment for AF-MSC+HB-EGF compared to AF-MSC alone. Administration of HB-EGF and MSC improved intestinal histology and intestinal permeability after I/R injury. The greatest improvement was with combined administration of HB-EGF+AF-MSC. CONCLUSIONS: Both HB-EGF alone and MSC alone can protect the intestines from I/R injury, with synergistic efficacy occurring when HB-EGF and AF-MSC are administered together.
Authors: S Tokumaru; S Higashiyama; T Endo; T Nakagawa; J I Miyagawa; K Yamamori; Y Hanakawa; H Ohmoto; K Yoshino; Y Shirakata; Y Matsuzawa; K Hashimoto; N Taniguchi Journal: J Cell Biol Date: 2000-10-16 Impact factor: 10.539
Authors: Amanda R Jensen; Natalie A Drucker; Jan P Te Winkel; Michael J Ferkowicz; Troy A Markel Journal: J Pediatr Surg Date: 2018-03-06 Impact factor: 2.545
Authors: Amanda R Jensen; Natalie A Drucker; Sina Khaneki; Michael J Ferkowicz; Troy A Markel Journal: Am J Physiol Gastrointest Liver Physiol Date: 2017-03-09 Impact factor: 4.052
Authors: Amanda R Jensen; Dominique L Doster; E Bailey Hunsberger; Morenci M Manning; Samantha M Stokes; Daria Barwinska; Keith L March; Mervin C Yoder; Troy A Markel Journal: Shock Date: 2016-07 Impact factor: 3.454
Authors: Maria Nikiforou; Carolin Willburger; Anja E de Jong; Nico Kloosterboer; Reint K Jellema; Daan R M G Ophelders; Harry W M Steinbusch; Boris W Kramer; Tim Wolfs Journal: Mol Med Date: 2016-04-14 Impact factor: 6.354